Close Menu

NEW YORK – Guardant Health said today that its Guardant360 CDx liquid biopsy test has received the CE mark for tumor mutation profiling in cancer patients with any solid tumor. The assay is also approved as a companion diagnostic to identify non-small cell lung cancer patients who may benefit from treatment with osimertinib (AstraZeneca's Tagrisso).

Guardant360 CDx is a targeted sequencing assay performed on blood samples, which detects alterations in a panel of 55 genes with established actionability in guiding the use of molecularly targeted cancer drugs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.